Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
暂无分享,去创建一个
Y. Song | Y. Bang | Soon‐Beom Kang | H. Lee | J. Nam | Jong-Hyeok Kim | S. Seo | Sang-Yoon Park | S. Ryu | K. Lee | Soon-Beom Kang